bms juno (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
94
Structured Review
Miltenyi Biotec
bms juno
Bms Juno, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms+juno/FR4+Antibody%2C+anti-mouse/pm41485560-175-10-11
Average 94 stars, based on 4 article reviews
Bms Juno, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms+juno/FR4+Antibody%2C+anti-mouse/pm41485560-175-10-11
Average 94 stars, based on 4 article reviews
bms juno - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
other:Article Title: Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium. Article Snippet: Shah: Article Title: Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study Article Snippet: Conflict of interest: COI declared - see note COI notes: Nirav N. Shah: reports participation on advisory boards and/or consultancy for GileadKite, Article Title: Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Article Snippet: word count: 224 Article word count: 2552 Tables : 1 Figures : 2 Supplemental figure :1 Supplemental tables : 5 ABSTRACT : Relapsed and/or refractory Richter transformation (RT) is generally associated with poor response to available therapies and short survival time.. As RT patients were excluded from participating in the pivotal studies of chimeric antigen receptor T cell therapy (CAR-T) for large B-cell lymphoma, there is paucity of information about the efficacy of CAR-T in RT.. Therefore, through the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, Relapsed and/or refractory Richter transformation (RT) is generally associated with poor response to available therapies and short survival time. Article Title: Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. Article Snippet: NNS reports participation on advisory boards and/or has received consultancy fees for Gilead-Kite, Article Title: Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. Article Snippet: NNS reports participation on advisory boards and/or has received consultancy fees for GileadKite, Article Title: Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study Article Snippet: 336 Conflicts of Interest 337 N.N.S. reports participation on advisory boards and/or consultancy for Gilead-Kite, BMS-Juno, Article Title: Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium. Article Snippet: Shah: Tundra Therapeutics: Current holder of stock options in a Article Title: Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study. Article Snippet: Word Count: 241 Manuscript Word Count: 3676 |